We use cookies on our website to improve the website and your experience.
Read moreReflecting on Vaccines Summit Ohio 2021
23 Mar 2021It has now been three weeks since Albumedix´ US Business Development Director Brian Macdonald attended VSOHIO21 and with many of the presentation just going live on Biogate Scientific Center´s YouTube channel, we continue to learn and reflect on the topics of this conference.
With many of our customers working with and developing vaccines, it is important that we keep our fingers on the pulse, by engaging with the people who are tackling the big challenges facing this industry today. VSOHIO21 covered topics ranging from global strategies of handling big viral outbreaks as we are experiencing with the COVID-19, to new vaccine advancements and essential technologies for vaccine research and development.
Having attended many vaccine focused conferences in the past decades we have witnessed exciting new technologies and platforms bringing increasingly more effective, practical and cost-efficient vaccines to people around the world. Exemplified most recently with Pfizer being the first to bring a mRNA vaccine to the market for widespread use.
A topic which we are noticing more now, and that Brian also took special note of at VSOHIO21, is the focus on technologies which can facilitate large scale production and especially mass-scale distribution with reduced cost and more practical logistics. Developing a stable vaccine formulation and maintaining this stability during transportation is key and several presentations at VSOHIO21 addressed this topic.
Brian highlights an interesting presentation from Leukocare on the topic of effective stabilization of viral vaccines and viral vector formulations using an algorithm-based development approach (Sabine Hauck's talk at VSOHIO21 - YouTube). The presentation shows an efficient pre-selection strategy of stabilizing excipients. A topic which we here in Albumedix are very engaged in with our partners and clients using albumin as an effective stabilizer of viral vector-based therapies and biopharmaceuticals. Having effective methods and strategies for identifying stable formulation of a drug candidate, as early as possible in development, will save a lot of time and money down the road.
Further interesting presentations were given, and we recommend tuning in to Biogate Scientific Center´s YouTube channel to view some of these!